UA67795C2 - Pharmaceutical composition for treating burn wounds containing miramystine - Google Patents

Pharmaceutical composition for treating burn wounds containing miramystine Download PDF

Info

Publication number
UA67795C2
UA67795C2 UA2001031868A UA2001031868A UA67795C2 UA 67795 C2 UA67795 C2 UA 67795C2 UA 2001031868 A UA2001031868 A UA 2001031868A UA 2001031868 A UA2001031868 A UA 2001031868A UA 67795 C2 UA67795 C2 UA 67795C2
Authority
UA
Ukraine
Prior art keywords
miramystine
pharmaceutical composition
burn wounds
treating burn
wounds containing
Prior art date
Application number
UA2001031868A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Yurii Semenovych Kryvoshein
Adolina Petrivna Rudko
Original Assignee
Yurii Semenovych Kryvoshein
Adolina Petrivna Rudko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yurii Semenovych Kryvoshein, Adolina Petrivna Rudko filed Critical Yurii Semenovych Kryvoshein
Publication of UA67795C2 publication Critical patent/UA67795C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the pharmaceutical composition for treating the burn wounds containing Miramystine and the gel-forming agent representing the modified derivatives of cellulose, tylose, or Enterosgel.

Description

ше Ге раниshe Ge rana

У 3-х хворих, яким пересадка була проведена без використання заявленого складу, його почали приміняти після появи ознак часткового розплавлення аутотрансплантатів, що призвело до швидкої ліквідації ГВ і збереження життєздатності лишившихся ділянок пересадженої шкіри.In 3 patients who were transplanted without using the declared composition, it was started to be used after the appearance of signs of partial melting of the autografts, which led to the rapid elimination of HV and preservation of the viability of the remaining areas of the transplanted skin.

У жодному випадку не була відмічена побічна дія складу або скарги хворих на неприємні відчуття при їх нанесенні. Навпаки, гелеподібний склад при нанесенні на ранову поверхню викликав зниження больових симптомів і відчуття печії.In no case was there a side effect of the composition or complaints of patients about unpleasant sensations when they were applied. On the contrary, the gel-like composition, when applied to the wound surface, caused a decrease in pain symptoms and a feeling of heartburn.

Як видно з табл.2. ефективність складу 1 практично не відрізняється від ефективності прототипу, що пов'язано з однаковою концентрацією мірамістину і недостатньою концентрацією гелеутворювача.As can be seen from Table 2. the effectiveness of composition 1 practically does not differ from the effectiveness of the prototype, which is associated with the same concentration of miramistin and insufficient concentration of the gelling agent.

В той же час ефективність складу 2 значно ефективніша за прототип, що при равній концентрації мірамістину підтверджує синергізм його з гелеутворювачем, який без мірамістину такого ефекту не дає (склад 8).At the same time, the effectiveness of composition 2 is much more effective than the prototype, which at an equal concentration of miramistin confirms its synergism with the gelling agent, which does not produce such an effect without miramistin (composition 8).

Заявлений склад може вироблятись фармацевтичною промисловістю тому що всі компоненти є промисловими зареєстрованими продуктами: мірамістин - реєстр. Ме 91/146/2 ентеросгель - реєстр. Ме П 98/88/6 тілоза - Сертифікат Ме РОСС ДЕ.АЯ 12.С0О 2205.The claimed composition can be produced by the pharmaceutical industry because all components are registered industrial products: miramistin - reg. Me 91/146/2 enterosgel - register. Me P 98/88/6 tylose - Certificate Me ROSS DE.AYA 12.С0О 2205.

UA2001031868A 2000-06-26 2001-03-20 Pharmaceutical composition for treating burn wounds containing miramystine UA67795C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2000116316A RU2185157C2 (en) 2000-06-26 2000-06-26 Composition for treating burn wounds

Publications (1)

Publication Number Publication Date
UA67795C2 true UA67795C2 (en) 2004-07-15

Family

ID=20236630

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001031868A UA67795C2 (en) 2000-06-26 2001-03-20 Pharmaceutical composition for treating burn wounds containing miramystine

Country Status (3)

Country Link
EA (1) EA003935B1 (en)
RU (1) RU2185157C2 (en)
UA (1) UA67795C2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101113A1 (en) 2010-02-19 2011-08-25 Megainpharm Gmbh Pharmaceutical comprising myramistin
MD481Z (en) * 2011-08-09 2012-09-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Method for treating I-IIIA-degree burns

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008039254A1 (en) 2008-08-20 2010-02-25 Megainpharm Gmbh Medicament, useful e.g. for treating infectious- and purulent inflammatory diseases of e.g. eyes, comprises benzyl-dimethyl-(3-(myristoylamino)-propyl)-ammonium chloride, dimethyl-(3-(myristoylamino)-propyl)-amine oxide and solvent
WO2014175757A1 (en) * 2013-04-22 2014-10-30 Общество с ограниченной ответственностью "Нанобиотех" Antiseptic veterinary formulation and methods for use thereof
RU2542376C1 (en) * 2013-07-30 2015-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Agent for pyoinflammatory processes in soft tissues and mucous membranes

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101113A1 (en) 2010-02-19 2011-08-25 Megainpharm Gmbh Pharmaceutical comprising myramistin
WO2011100994A1 (en) 2010-02-19 2011-08-25 Megainpharm Gmbh Pharmaceutical comprising myramistin
EA022283B1 (en) * 2010-02-19 2015-12-30 Мегаинфарм Гмбх Pharmaceutical comprising benzyldimethyl[3-(myristoylamino)propyl]ammonium chloride
MD4411C1 (en) * 2010-02-19 2016-11-30 Megainpharm Gmbh Pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)-ammonium chloride and its use for the treatment and prevention of infectious and pyoinflammatory diseases of different etiology and localization
MD481Z (en) * 2011-08-09 2012-09-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Method for treating I-IIIA-degree burns

Also Published As

Publication number Publication date
EA200100559A1 (en) 2002-02-28
RU2185157C2 (en) 2002-07-20
EA003935B1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
ATE213164T1 (en) USE OF NONA- AND DECAPEPTIDES FOR PRODUCING A MEDICINAL PRODUCT TO FIGHT AIDS
HUP0301518A2 (en) Dry powder composition for the treatment of respiratory diseases and process for its preparation
ES2195866T3 (en) MULTIUS ACID COMPOSITIONS.
ATE188341T1 (en) PRESERVATIVES AND METHODS FOR TREATING WOOD
DE68924537D1 (en) COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO.
DE69526937T2 (en) USE OF METHANBISPHOSPHONIC ACID DERIVATIVES FOR TREATING LOSSED PROSTHESES
ATE135208T1 (en) USE OF NERVOIC ACID AND LONG CHAIN FATTY ACIDS TO TREAT DEMYELINIZING DISEASES
ATE415962T1 (en) USE OF ASIATIC ACID OR ASIATICOSIDE TO TREAT CANCER
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
ATE225125T1 (en) SOLUTION FOR THE PRESERVATION OF ORGANS OR TISSUES OR PARTS THEREOF FROM HUMAN OR ANIMALS
RS50148B (en) Use of docetaxel for treating hepatocellular carcinoma
DE69803773T2 (en) COMPOSITION CONTAINING YOHIMBINE AND ARGININE FOR TREATING ERECTILE MALFUNCTION
UA67795C2 (en) Pharmaceutical composition for treating burn wounds containing miramystine
BG105275A (en) Tan-1057 derivatives
DE69927260D1 (en) TOPICAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN OR CIRCULATORY DISEASES OF INFLAMMATORY, IMMUNE, PROLIFERATIVE OR DEGENERATIVE BASIS
DE60206280D1 (en) USE OF EXTRACTS FROM GINKGO BILOBA FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SARCOPENIA
ATE548048T1 (en) ONCOMODULIN FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE60128009D1 (en) USE OF SARP-1 FOR THE TREATMENT AND / OR PREVENTION OF SCLERODERMA
DE69804597T2 (en) OIL FOR TREATMENT OF BURNS AND OTHER SKIN DISEASES
ATE193206T1 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
DE602004029993D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
ATE466587T1 (en) VALERIANA OFFICINALIS EXTRACT FOR THE TREATMENT OF SLEEP APNEA OR HYPOPNEA
BR9206760A (en) Amalgam for fillings and method of preparing amalgam components
ATE164766T1 (en) COMPOSITION OF ASPHODELUS TO INCREASE THE NUMBER OF WHITE BLOOD CELLS
ATE165509T1 (en) AVERMECTINE AND MILBEMYCINE FOR THE TREATMENT OF PARACITIC INFECTIONS IN DOGS